{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Kymera Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"KYMR"},"Address":{"label":"Address","value":"200 ARSENAL YARDS BOULEVARD,SUITE 230, WATERTOWN, Massachusetts, 02472, United States"},"Phone":{"label":"Phone","value":"+1 857 285-5300"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients."},"CompanyUrl":{"label":"Company Url","value":"https://www.kymeratx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Jared Gollob","title":"Chief Medical Officer"},{"name":"Jeremy G. Chadwick","title":"Chief Operating Officer"},{"name":"Juliet Williams","title":"Head-Research"},{"name":"Kevin Dushney","title":"Senior VP-Information Technology & Operations"},{"name":"Nello Mainolfi","title":"President, Chief Executive Officer & Director"},{"name":"Vijay Sabesan","title":"Senior VP-Technical Operations & Quality"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}